Clinical trial · Interventional
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
A Phase 1/2 Study of BMS-908662 (XL281) Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
NCT01086267CI-TRIAL-00022737completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with cetuximab; and then to evaluate the tumor response to BMS-908662 when administered alone or in combination with cetuximab
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-908662 | Drug | — | UNRESOLVED |
| Cetuximab | Drug | Cetuximab | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- BMS-908662 (A1)
- description
- Phase 1
- interventionNames
- Drug: BMS-908662
- type
- EXPERIMENTAL
- label
- Cetuximab (A1)
- description
- Phase 1
- interventionNames
- Drug: Cetuximab
- type
- EXPERIMENTAL
- label
- BMS-908662 (B1)
- description
- Phase 2
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects with K-RAS (codon 12 or 13) or B -RAF (V600E) mutation positive advanced or metastatic colorectal cancer who have relapsed or are refractory to 2 or more standard systemic anticancer regimes for metastatic disease, or are intolerant to existing therapies. * Histologic or cytologic confirmation of the diagnosis. * Eastern Cooperative Oncology Group (ECOG) ≤ 1 * Adequate organ \& marrow function. Exclusion Criteria: * Uncontrolled or significant cardiovascular disease. * Phase 2: Prior therapy with a RAF inhibitor.
References
Publications (0)
Data not yet available
No reference posted for this study.